Results 141 to 150 of about 101,656 (254)
Use of Granulocyte-Colony Stimulating Factor for Beta-Lactam Induced Neutropenia in Children With Bacterial Meningitis. [PDF]
Yen CY, Kaplan SL, Palazzi DL, Stimes G.
europepmc +1 more source
Targeting KRAS for cancer therapy
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia +4 more
wiley +1 more source
Multimodal evaluation of mannose engineered poly lactic glycolic acid nanoparticles with granulocyte colony stimulating factor focused delivery to bone marrow for neutropenia. [PDF]
Karwasra R +7 more
europepmc +1 more source
The flow of this trial and the treatment schedule of adjuvant chemotherapy with nedaplatin plus docetaxel for completely resected non‐small cell lung cancer (NSCLC) (A). The primary endpoint of this study was tolerability, assessed by the completion rate of the planned four chemotherapy cycles. As a result, it was 74.3%, exceeding that reported for the
Koji Teramoto +9 more
wiley +1 more source
Granulocyte colony-stimulating factor-associated aortitis in a man with advanced prostate cancer. [PDF]
Ikadai R, Kitano G, Kato M, Kojima T.
europepmc +1 more source
The gut microbiota metabolite indole ‐ 3 ‐ propionic acid(IPA) enhanced the inhibitory effect of SCB on tumor growth in HCC mice. IPA upregulated IL‐12A expression through facilitating acetylation of H3K27 in DCs. IPA elevated IL‐12A expression in DCs to promote CD8+ T cell anti‐tumor immunity and ultimately enhances the efficacy of SCB therapy against
Rui Zhao +7 more
wiley +1 more source
Sarcopenia attenuates the efficacy of PEGylated granulocyte colony-stimulating factor in preventing febrile neutropenia. [PDF]
Go SI +5 more
europepmc +1 more source
In this analysis of a diverse cohort of 500 patients with previously untreated DLBCL in a real‐world clinical setting, Pola‐R‐CHP demonstrated high response rates at end‐of‐treatment, which were consistent among the overall population, in patients > 80 years and regardless of International Prognostic Index status and cell of origin subtypes.
Takahiro Kumode +21 more
wiley +1 more source
Granulocyte Colony-Stimulating-Factor-Producing Bladder Carcinoma: A Case Report and Literature Review. [PDF]
Yamashita K +7 more
europepmc +1 more source

